AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Quantum Genomics Share Issue/Capital Change 2019

Jan 14, 2019

1617_dva_2019-01-14_027daf66-0e28-4cee-82c8-241c431879d4.pdf

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

Information relating to the total number of voting rights forming the share capital

Article L. 238-8-II of the French commercial Code and article 223-16 of the AMF (French Financial Markets Authority) general regulation

Date	Total number of shares forming the share capital	Total number of voting rights
31/12/2018	15,774,349(1)	Total number of theoretical voting rights(2) :	17,559,115
		Total number of voting rights that may be exercised(3) :	17,502,360

(1) including 4,427,000 new shares issued since April 2018 under the equity line financing agreement concluded with Kepler Cheuvreux in March 2018 (see press release dated 05/03/2018), of which 2,050,000 issued in the month of December 2018 at an average price of €5,02 per share representing a 1,80% discount.
(2) after taking into account the shares with double voting rights and the treasury shares.
(3) after deducting the shares without voting right (treasury shares).

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on its 20-plus years of basic and clinical research at some of the largest French laboratories: the French National Institute of Health and Medical Research (INSERM), the French National Centre for Scientific Research (CNRS), the Collège de France, and Paris-Descartes University. The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with heart failure dies within five years).

Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).

For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn

Contact information